OR WAIT 15 SECS
Sigma-Aldrich has reached an acquisition agreement with Cell Marque to further their antibody portfolio.
Sigma-Aldrich announced on Oct. 3, 2014, that it had agreed to acquire Cell Marque, a company focused on producing and marketing antibodies for diagnostic immunohistochemistry, for an undisclosed price. The acquisition will strengthen Sigma-Aldrich’s antibody portfolio.
"We expect that Cell Marque's strong in vitro diagnostic antibody product lines and solid relationships with pathologists and companies that provide automated staining instrumentation will broaden the diagnostic health reach of Sigma-Aldrich," Frank Wicks, PhD, president of Sigma-Aldrich's Applied Business Unit, said in a press release.
Related Content:PharmTech News